Download PDF
Neuropediatrics 2007; 38(5): 251-252
DOI: 10.1055/s-2007-985901
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Congenital Gingival Hyperplasia in a Neonate with Foetal Valproate Syndrome

M. Rodríguez-Vázquez 1 , M. C. Carrascosa-Romero 2 , J. M. Pardal-Fernández 3 , I. Iniesta 4
  • 1Department of Dermatology, Hospital General Universitario de Albacete, Albacete, Spain
  • 2Department of Neonatology, Hospital General Universitario de Albacete, Albacete, Spain
  • 3Depatment of Clinical Neurophysiology, Hospital General Universitario de Albacete, Albacete, Spain
  • 4Department of Neurology, The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK
Further Information

Publication History

received 15.05.2006

accepted 04.07.2007

Publication Date:
10 March 2008 (online)

Also available at
    Permissions and Reprints

Abstract

There are several causes of gingival hyperplasia and one of the most well-known is drug-induced gingival enlargement. Nevertheless, causes of congenital gingival enlargement include only hereditary and metabolic disorders. Only one case of drug-induced congenital gingival hyperplasia has been reported. We present the second neonate with gingival hyperplasia in the context of foetal valproate syndrome and review the literature.

Key words

gingival hyperplasia - embryopathy - valproic acid

References

  • 1 Anderson HH, Rapley JW, Williams DR. Gingival overgrowth with valproic acid: a case report.  ASDC J Dent Child. 1997;  64 294-297
    PubMedGoogle Scholar
  • 2 Bailey CJ, Pool RW, Poskitt E, Harris F. Valproic acid and fetal abnormality.  Br Med J. 1983;  286 190
    PubMedGoogle Scholar
  • 3 Behari M. Gingival hyperplasia due to sodium valproate.  J Neurol Neurosurg Psychiatry. 1991;  54 279-280
    PubMedGoogle Scholar
  • 4 Canun S, Guevara-Sangines EG, Elvira-Morales A, Sierra-Romero MC, Rodriguez-Asbun H. Hypertrichosis terminalis, gingival hyperplasia, and a characteristic face: a new distinct entity.  Am J Med Genet. 2003;  116 278-283
    PubMedGoogle Scholar
  • 5 Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid.  J Pediatr. 1980;  97 332-333
    PubMedGoogle Scholar
  • 6 Gorlin RJ, Cohen  Jr  MM, Hennekam RCM. Teratogenic agents. In: Syndromes of the Head and Neck, 4th edn, Oxford University Press 2001: 29-31
    Google Scholar
  • 7 Khera P, Zirwas MJ, English JC. Diffuse gingival enlargement.  J Am Acad Dermatol. 2005;  52 491-499
    CrossrefPubMedGoogle Scholar
  • 8 Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid.  Can Fam Physician. 2006;  52 441-442
    PubMedGoogle Scholar
  • 9 Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.  Am J Med Genet. 2001;  98 168-175
    CrossrefPubMedGoogle Scholar
  • 10 Perucca E. Birth defects after prenatal exposure to antiepileptic drugs.  Lancet Neurology. 2005;  4 781-786
    CrossrefPubMedGoogle Scholar
  • 11 Stoll C, Audeoud F, Gaugler C, Bernardin A, Messer J. Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero.  Genetic Counseling. 2003;  14 289-298
    PubMedGoogle Scholar
  • 12 Syrjanen S, Syrjanen K. Hyperplastic gingivitis in a child receiving sodium valproate treatment.  Proc Finn Dent Soc. 1979;  75 95-98
    PubMedGoogle Scholar
  • 13 Tatum WO. Use of antiepileptic drugs in pregnancy.  Expert Rev Neurother. 2006;  6 1077-1086
    CrossrefPubMedGoogle Scholar

Correspondence

M. Rodríguez-Vázquez

Dermatología

Hospital General Albacete

Hermanos falcó 37 albacete

02006 Albacete

Spain

Phone: +34/096/759 71 00

Email: mrodvaz@yahoo.es